Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLR Allarity Therapeutics Inc

Pre-Mkt 09-04 06:45:13 EDT

1.43

+0.02

+1.42%

盘前1.46

+0.03+2.36%

04:05 EDT

High1.48	Low1.39	Vol44.21K
Open1.43	D1 Closing1.41	Amplitude6.35%
Mkt Cap22.62M	Tradable Cap22.59M	Total Shares15.82M
T/O63.86K	T/O Rate0.28%	Tradable Shares15.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALLR","market":"US","secType":"STK","nameCN":"Allarity Therapeutics Inc","latestPrice":1.43,"timestamp":1788465600000,"preClose":1.41,"halted":0,"volume":44209,"hourTrading":{"tag":"盘前","latestPrice":1.4637,"preClose":1.43,"latestTime":"04:05 EDT","volume":1,"amount":1.4637,"timestamp":1788509119450,"change":0.0337,"changeRate":0.023566,"amplitude":0},"delay":0,"changeRate":0.014184397163120581,"floatShares":15794100,"shares":15818980,"eps":-0.789506,"marketStatus":"Pre-Mkt","change":0.02,"latestTime":"09-04 06:45:13 EDT","open":1.43,"high":1.4796,"low":1.39,"amount":63863.494691700005,"amplitude":0.063546,"askPrice":1.48,"askSize":1000,"bidPrice":1.24,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.789506,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.4637,"preClose":1.43,"latestTime":"04:05 EDT","volume":1,"amount":1.4637,"timestamp":1788509119450,"change":0.0337,"changeRate":0.023566,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.41,"preClose":1.43,"latestTime":"19:51 EDT","volume":1986,"amount":2823.4143,"timestamp":1788479466779,"change":-0.02,"changeRate":-0.013986,"amplitude":0.027972},"volumeRatio":0.46535397572159715},"requestUrl":"/m/hq/s/ALLR/wiki","defaultTab":"wiki","newsList":[{"id":"2659173641","title":"Allarity Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173641","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173641?lang=en_us&edition=fundamental","pubTime":"2026-08-15 21:32","pubTimestamp":1786800758,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAllarity Therapeutics IncALLR.OQreported a quarterly adjusted loss of 21 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260815:nL8N44C04F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149567","title":"Allarity Therapeutics Q2 Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149567","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149567?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:10","pubTimestamp":1786709400,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Q2 loss narrows as expenses fallOverviewCancer drug developer's Q2 net loss narrowed yr/yr, operating expenses declinedCompany ended Q2 with $26.9 mln in cash and restricted cash","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","NCNA","IMNM","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149853","title":"Allarity Therapeutics Q2 Net Loss Per Share $0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149853?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLX40BF1N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146781","title":"Allarity Therapeutics Q2 Operating Expenses USD 2.671 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146781?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLX40BF1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","PLTM","BK4539","BK4503","ALLR","BK4551","CLIA","LENZ","CDMO","BMED","BK4139","BK4023","IDNA","BK4535","API","NVIB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659528461","title":"Allarity Therapeutics Inc Expected to Post a Loss of 25 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2659528461","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659528461?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:32","pubTimestamp":1786624341,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc <ALLR.OQ> expected to post a loss of25cents a share - Earnings PreviewAllarity Therapeutics IncALLR.OQALLR.Ois expected to  show no change in quarterly revenue when it reports  results on August 15  for the period ending June 30 2026LSEG's mean analyst estimate for Allarity Therapeutics Inc is for a loss of 25 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Allarity Therapeutics Inc is $10.25, about 632.1% above its last closing price of $1.40This summary was machine generated August 13 at 12:32 GMT.  All figures in US dollars unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987314","title":"Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987314?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:00","pubTimestamp":1783425600,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics is now poised to run its DRP testing in-house in a CLIA-certified laboratory environmentThe FDA requires that biomarker testing to select patients for registration trials must be","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323142/0/en/Allarity-Therapeutics-Announces-CLIA-Certification-Clearing-the-Path-for-Advancing-DRP-Testing-for-FDA-Registration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMS","HYLG","BK4539","LABU","LU0949170772.SGD","LU2637428348.USD","LU0661504455.SGD","IDNA","ALLR","BK4208","LU1894683348.USD","LU1003077747.HKD","GDOC","LENZ","BK4139","LU0738911758.USD","MEDX","BMED","LU0553294199.USD","LU2346227817.USD","BK4585","BK4007","CLIA","LU1894683264.USD","LU0545039389.USD","BK4588","LU2500361329.USD","PLTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964908","title":"Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib Drp® Companion Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964908","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964908?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:22","pubTimestamp":1783322525,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Allarity Therapeutics Inc::*ALLARITY THERAPEUTICS ANNOUNCES THE GRANT OF ESSENTIAL U.S. PATENT FOR ITS STENOPARIB DRP COMPANION DIAGNOSTIC*ALLARITY THERAPEUTICS - GRANTED PATENT TE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSDC10xn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647896555","title":"Allarity Therapeutics - Has Patent Protection for Stenoparib Drp in Europe and Australia into 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2647896555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647896555?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:08","pubTimestamp":1782821308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320IQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555895","title":"Allarity Therapeutics - Granted Patent Term Extends into April 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647555895?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:08","pubTimestamp":1782821308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320IQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553237","title":"Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553237?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:00","pubTimestamp":1782820800,"startTime":"0","endTime":"0","summary":"Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Compan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319620/0/en/Allarity-Therapeutics-Announces-the-Grant-of-Essential-U-S-Patent-for-Its-Stenoparib-DRP-Companion-Diagnostic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902479","title":"Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902479","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645902479?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:11","pubTimestamp":1782130268,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics flagged its ongoing Phase 2 study of stenoparib in advanced platinum-resistant or platinum-ineligible ovarian cancer at ESMO Gynaecological Cancers Congress 2026.Trial-in-progress poster was presented June 18, 2026 in Copenhagen, outlining study design and clinical rationale rather than results.Management framed the study as positioning stenoparib as a potential new, more tolerable option for a high-need ovarian cancer segment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6NCtRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083205","title":"Allarity to present trial-in-progress poster on Phase 2 stenoparib trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083205?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:18","pubTimestamp":1781785086,"startTime":"0","endTime":"0","summary":"Allarity (ALLR) Therapeutics announced that it will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-to-present-trial-in-progress-poster-on-phase-2-stenoparib-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-to-present-trial-in-progress-poster-on-phase-2-stenoparib-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644835700","title":"Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO Gynaecological Cancers Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644835700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644835700?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:04","pubTimestamp":1781784286,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics announced a Trial-in-Progress poster for its ongoing Phase 2 stenoparib study in advanced platinum-resistant or platinum-ineligible ovarian cancer.The poster was presented June 18, 2026 at the ESMO Gynaecological Cancers Congress in Copenhagen.No results were presented; the disclosure focused on study rationale and design, with no new clinical outcomes.The trial aims to evaluate whether stenoparib can deliver durable clinical benefit in a hard-to-treat ovarian cancer population.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL18RnV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","NDAQ","SG9999014013.SGD","BK4588","ALLR","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640926152","title":"Allarity Therapeutics sets CEO consulting pay at SEK 6 million plus USD 163,043 for 2026 under amended services agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640926152","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640926152?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:11","pubTimestamp":1780434688,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics entered an amended and restated management services agreement effective June 1, 2026 with Ljungaskog Consulting AB, owned by CEO Thomas H. Jensen.2026 base pay set at SEK 6 million paid 80% in Swedish krona, 20% in US dollars totaling USD 163,043; $100,000 signing bonus removed.Annual bonus capped at 60% of monthly fees paid in a calendar year; payout due by March 15 following year-end.Company termination for convenience now requires 30 days’ notice, triggers 12 months of monthly fees paid semi-monthly, subject to release and cooperation conditions.Good Reason exit also triggers 12 months of monthly fees, replacing a prior nine-month payment structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL6NvMXf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635053272","title":"Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635053272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635053272?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:59","pubTimestamp":1778882340,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAllarity Therapeutics Inc ALLR.OQ reported a quarterly adjusted loss of 17 cents per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S28Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635637030","title":"Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2635637030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635637030?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:30","pubTimestamp":1778877001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA73XK7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037918","title":"Allarity Therapeutics Q1 FY26 net loss narrows to $2.75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037918","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037918?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:08","pubTimestamp":1778875689,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics posted a net loss of USD 2.75 million for the quarter ended March 31, 2026, slightly wider than the USD 2.73 million loss a year earlier.Revenue turned to USD 25,000 from no revenue in the prior-year quarter, reflecting license revenue from DRP testing services.Operating loss narrowed to USD 2.69 million from USD 3.04 million as operating expenses fell to USD 2.71 million, led by research and development spending of USD 1.3 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL837phz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634234359","title":"Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634234359","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634234359?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:21","pubTimestamp":1778527317,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics named Jesper Hoeiland as a director in an initial Form 3 filing dated June 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3HP1BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633745995","title":"Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633745995","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633745995?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244313,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics CEO Thomas Jensen to speak at Precision Medicine Forum Europe 2026 in Stockholm on May 11-12, 2026.On May 11, Jensen scheduled to present “Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical Trials” from 10:20-10:40 CEST in oncology track.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL86JlnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4588","LU2210150020.SGD","NDAQ","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","ALLR","BK4139","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allarity.com","stockEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0916},{"period":"3month","weight":-0.1118},{"period":"6month","weight":0.1532},{"period":"1year","weight":-0.2143},{"period":"ytd","weight":0.3241}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.137955},{"month":2,"riseRate":0,"avgChangeRate":-0.233915},{"month":3,"riseRate":0.4,"avgChangeRate":-0.236538},{"month":4,"riseRate":0.4,"avgChangeRate":-0.249609},{"month":5,"riseRate":0.4,"avgChangeRate":-0.030679},{"month":6,"riseRate":0.2,"avgChangeRate":-0.321914},{"month":7,"riseRate":0.2,"avgChangeRate":-0.176702},{"month":8,"riseRate":0.4,"avgChangeRate":0.069331},{"month":9,"riseRate":0.4,"avgChangeRate":-0.245675},{"month":10,"riseRate":0,"avgChangeRate":-0.290985},{"month":11,"riseRate":0,"avgChangeRate":-0.125579},{"month":12,"riseRate":0.25,"avgChangeRate":-0.118424}],"exchange":"NASDAQ","name":"Allarity Therapeutics Inc","nameEN":"Allarity Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allarity Therapeutics Inc,ALLR,Allarity Therapeutics Inc股票,Allarity Therapeutics Inc股票老虎,Allarity Therapeutics Inc股票老虎国际,Allarity Therapeutics Inc行情,Allarity Therapeutics Inc股票行情,Allarity Therapeutics Inc股价,Allarity Therapeutics Inc股市,Allarity Therapeutics Inc股票价格,Allarity Therapeutics Inc股票交易,Allarity Therapeutics Inc股票购买,Allarity Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction